In patients with HER2-overexpressing breast cancer, higher pretreatment survivin RNA levels correlated with poorer responses to trastuzumab, indicating BIRC5’s involvement in primary Herceptin resistance [32]. The gene discussed is ERBB2; the disease is breast carcinoma.